

PRODUCT LIST

October 2024

State of the art B2B

Ophthalmics available

INN	STRENGTH	Shelf life	PRESERVATIVE FREE	PRESENTATION	THERAPY DAYS	STABILITY ZONE II	STABILITY ZONE IV	PRODUCT ML	STORAGE CONDITIONS	BATCH SIZE	POLPHARMA'S BRAND	BRAND NAME
Anti-allergy (Eye drops solution)												
Olopatadine	1mg/ml	36 months	Yes	Nemera Novelia®	30 90	Yes Yes	No TBD	5.0 3 x 5.0	Store below 30oC. After first opening use in 90 days.	43 860	Olodon® free	Olodon® /Nolodon®/ Starelltec®
Anti- infectives Eye (Eye drops solution)												
Moxifloxacin	5mg/ml	24 months	No	Regular bottle	30	Yes	No	5.0	Once opened - store for 28 days at a temperature below 30oC	40 000	Floxamic Neo®	Floxamic® / Ekara®/ Genaxil®
Glaucoma (Eye drops solution)												
Bimatoprost	0.3mg /ml	24 months	Yes	Nemera Novelia®	30	Yes	No	3.0	Once opened, do not store above 25oC	70 423 25 510	Bimifree®	Bimi® / Iricryn®
Bimatoprost/ Timolol	(0.3mg / 5mg) /ml	24 months	Yes	Nemera Novelia®	30 90	Yes	No	3.0	Once opened, do not store above 25oC	70 423 25 510	Bimifree® Combi	Bimiduo® / Bapiri® / Bitifrin®
Brimonidine	2mg /ml	24 months	Yes	Nemera Novelia®	30 90	Yes Yes	No No	5.0 3 x 5.0	Store below 30oC. After first opening use in 90 days.	43 103 43 103	Briglau® PPH Free	Briglau®/Briglafre® /Rivotra®

*Polpharma Group API CA: Dossier suitable for Canadian market "Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products

Apixaban, Rivaroxaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met."

Dorzolamide	20mg/ml	24 months	Yes	Nemera Novelia®	30 60	Yes Yes	No No	5.0 10.0	Once opened, do not store above 25oC	45 455 22 727	Nodofree®	Dimaz® /Itoco® / Optipres®
Dorzolamide/Timolol	(20mg/5mg) /ml	24 months	Yes	Nemera Novelia®	30 60	Yes Yes	No No	5.0 10.0	Once opened, do not store above 25oC	45 455 22 727	Nodofree® Combi	Tidimaz®/Codimaz®/Olatain®/Olahyd®/Amiptic®
Latanoprost	0,05mg/ml	24 months	Yes	Aeropump 3K®	30 90	Yes Yes	In progress In progress	2.5 7.5	Do not freeze. Do not store above 25oC Zone IV- 90 days in use study in progress.	54 000 18 000	Xalofree®	Lifog®/ Lotacryn®/Loravis®/Lagakomi®
Latanoprost/Timolol	(0.05mg / 5mg) / ml	Yes	Aeropump 3K®	30 90	In progress In progress	2.5 7.5	54 000 18 000	Xalopt ic® Combi	Lifoduo®/Lotaduo®/Loraduo®			
Travoprost	0.04mg / ml	24 months	Yes	Aeropump 3K®	30 90	Yes Yes	In progress In progress	2.5 7.5	Do not freeze. After first opening keep the bottle in the outer carton in order to protect from light.	55 000 22 000	Tipifree®	Tipifree®/Traslor®
Travoprost/Timolol	(0.04mg / 5mg) / ml	24 months	Yes	Aeropump 3K®	30 90	In progress In progress	In progress In progress	2.5 7.5	Do not freeze. After first opening keep the bottle in the outer carton in order to protect from light.	55 000 22 000	Tipifree® combi	-
Acetazolamide	250mg	60 months	No	Tablets	30	No	No	300 000	Diuramid®	Diuramid®/ Diacarb®		
Tropicamide	5mg/ml 10mg / ml	36 months	No No	Regular bottle Regular bottle	30 30	Yes Yes	No No	2 x 5 2 x 5	Store below 25oC. After first opening use in 4 weeks.	192 000 594 000	Topicamidum WZF®	-

*Polpharma Group API CA: Dossier suitable for Canadian market "Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products

Apixaban, Rivaroxaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met."

Tobramycin / Dexamethasone	(3mg +1mg) /ml	24 months	No	Regular bottle	30	Yes	No	5	Store below 25oC. After first opening use in 4 weeks.	40 000	Trobosopt-Dex®	-
----------------------------	----------------	-----------	----	----------------	----	-----	----	---	---	--------	----------------	---

Ophthalmics under development

INN	INDICATION	DEVELOPMENT PHASE
OR11	Red eye	Lab development
OD41	Dry eye	Lab development
OD31	Dry eye	Lab development
O111	Infection	Lab development
O21	Glaucoma	Lab development

**Polpharma Group API CA: Dossier suitable for Canadian market "Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products*

Apixaban, Rivaroxaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met."



FARMAPROJECTS

Carrer Provença 392, 6^a Planta

08025 Barcelona (Spain)

Phone +34 93 508 05 00

email: sales@farmaprojects.com

www.farmaprojects.com

© 2023, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department